NEW YORK--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, will present new efficacy data from Phase 1 and 2 clinical trials of Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature. These results indicate that treatment with Vascugel® improved patency and extended time to first intervention in patients with end-stage renal disease (ESRD) that need permanent arteriovenous (AV) access for dialysis compared to placebo. Data also show that treatment with Vascugel® resulted in accelerated vein remodeling for patients receiving an AV fistula (AVF) and increased lumen diameter for patients receiving an AV graft (AVG) compared to placebo. The data will be presented today during a session at the 35th Annual VEITHsymposium™ in New York City, New York, and build on the excellent safety results from these trials presented earlier this month at the American Society of Nephrology Annual Meeting.
